TRIAL TO COMPARE ADJUVANT ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOTERE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this phase III trial are to determine whether four cycles of post-operative Adriamycin (A:60mg/m2), Taxotere (T:60mg/m2), and Cyclophosphamide (C:600mg/m2) administered concurrently will more effectively prolong disease-free survival (DFS) and overall survival (S) of patients with node-positive breast cancer than will four cycles of AC (A:60mg/m2 and C:600mg/m2) followed by four cycles of T (100mg/m2); and if four cycles of post-operative AT (A:60mg/m2 and T:60mg/m2) is at least as efficacious as the above two regimens containing cyclophosphamide.